Effects of Chondroitinase and Training in Acute SCI
Award amount
$156,491Program and phase
SBIR · Phase IAward year
2005Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Acorda Therapeutics, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- R5D3FUPFFPK4
- Solicitation number
- PHS2005-2
- Topic code
- Not reported
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Chimeric proteins for the treatment of spinal cord injury
- Molecular Evolution of Chondroitinase ABCI for SCI
- Release Chondroitinase Systems for Spinal Cord Injury
- HUMAN MONOCOLONAL ANTIBODIES FOR CNS REMYELINATION
- Tenascin-C-Fragments for Spinal Cord Regeneration
Research funding history
10 SBIR/STTR records share this UEI (1996–2005). Reported award amounts total $2,216,009. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services